SenesTech (SNES) 10-Q/A 6 Nov 17 2017 Q1 Quarterly report (amended) Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2017	Nov. 01, 2017
Document And Entity Information [Abstract]
Document Type	10-Q/A
Amendment Flag	true
AmendmentDescription	EXPLANATORY NOTE SenesTech, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-Q/A to amend its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2017, filed with the Securities and Exchange Commission (“SEC”) on May 15, 2017 (the “Q1 Quarterly Report”) solely to add a summary of a significant accounting policy to “Item 1. Financial Statements — Notes to Condensed Financial Statements —Note 2. Summary of Significant Accounting Policies.” The remainder of the Quarterly Report on Form 10-Q is included for convenience only and, except for corresponding updates to the cover page, exhibit index, signature page, and references to the amended Annual Report on Form 10-K, reflects the contents of the Q1 Quarterly Report. This Amendment No. 1 has not been updated to reflect any events occurring after the filing of the Q1 Quarterly Report.
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Entity Registrant Name	SenesTech, Inc.
Entity Central Index Key	1,680,378
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	SNES
Entity Common Stock, Shares Outstanding		10,389,497

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 5,363	$ 11,826
Investment in securities held to maturity	2,961	0
Accounts receivable	6	10
Prepaid expenses	247	337
Inventory	111	57
Deposits	205	9
Total current assets	8,893	12,239
Property and equipment, net	702	631
Total assets	9,595	12,870
Current liabilities:
Short-term debt	50	45
Accounts payable	185	351
Accrued contract cancellation settlement	0	1,000
Accrued expenses	662	371
Notes payable, related parties	26	30
Total current liabilities	923	1,797
Notes payable, related parties	0	6
Long-term debt, net	141	138
Common stock warrant liability	60	69
Deferred rent	38	33
Total liabilities	1,162	2,043
Stockholders' equity:
Common stock, $0.001 par value, 100,000,000 shares authorized, 10,161,042 and 10,157,292 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively	10	10
Additional paid-in capital	72,826	72,069
Stock subscribed, but not issued, consisting of 44,750 and 4,750 shares at March 31, 2017 and December 31, 2016, respectively	363	59
Accumulated deficit	(64,766)	(61,311)
Total stockholders' equity	8,433	10,827
Total liabilities and stockholders' equity	$ 9,595	$ 12,870

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	10,161,042	10,157,292
Common Stock, Shares, Outstanding	10,161,042	10,157,292
Common Stock, Shares Subscribed but Unissued	44,750	4,750

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue:
License revenue	$ 0	$ 46
Sales	7	0
Total revenue	7	46
Cost of sales	4	0
Gross profit	3	46
Operating expenses:
Research and development	823	470
General and administrative	2,639	1,975
Total operating expenses	3,462	2,445
Net operating loss	(3,459)	(2,399)
Other income (expense):
Interest income	10	0
Interest expense	(13)	(31)
Interest expense, related parties	(1)	(17)
Loss on extinguishment of unsecured promissory note	0	(9)
Other income (expense)	8	(32)
Total other income (expense)	4	(89)
Net loss	(3,455)	(2,488)
Series A convertible preferred stock dividends	0	(30)
Net loss and comprehensive loss	$ (3,455)	$ (2,518)
Weighted average common shares outstanding - basic and fully diluted (in shares)	10,160,917	4,409,135
Net loss per common share - basic and fully diluted (in dollars per shares)	$ (0.34)	$ (0.56)

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (3,455)	$ (2,488)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on investments held to maturity	(9)	0
Amortization of discounts on investments held to maturity	5	0
Depreciation and amortization	59	46
Stock-based compensation	1,061	1,131
Non-cash charge for settlement of dispute	0	300
Amortization of debt discount	0	20
(Gain) Loss on remeasurement of common stock warrant liability	(9)	2
Loss on extinguishment of unsecured promissory note	0	9
(Increase) decrease in current assets:
Accounts receivable	4	13
Prepaid expenses	90	0
Inventory	(54)	0
Deposits	(196)	0
Increase (decrease) in current liabilities:
Accounts payable	(166)	108
Accrued contract cancellation settlement	(1,000)	0
Accrued expenses	291	38
Deferred rent	5	0
Deferred revenues	0	(46)
Net cash used in operating activities	(3,374)	(867)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of securities held to maturity	(2,957)	0
Purchase of property and equipment	(130)	(7)
Net cash used in investing activities	(3,087)	(7)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds received on unissued shares of common stock	0	50
Proceeds from the issuance of series B convertible preferred stock	0	671
Proceeds from the issuance of notes payable	21	326
Repayments of notes payable	(6)	(2)
Repayments of notes payable, related parties	(10)	(35)
Repayments of capital lease obligations	(7)	(5)
Payment of deferred offering costs	0	(216)
Proceeds from exercise of stock options and warrants	0	195
Net cash (used in) provided by financing activities	(2)	984
NET CHANGE IN CASH	(6,463)	110
CASH AT BEGINNING OF PERIOD	11,826	141
CASH AT END OF PERIOD	5,363	251
SUPPLEMENTAL INFORMATION:
Interest paid	14	16
Income taxes paid	0	0
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance of series B convertible preferred stock in connection with conversion of convertible notes and notes payable	0	16
Issuance of shares of common stock upon conversion of Series B convertible preferred stock	0	260
Debt discount on convertible notes	0	9
Original issue discount	$ 0	$ 179

Organization and Description of

Organization and Description of Business	3 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1 - Organization and Description of Business SenesTech, Inc. (the “Company”) was formed in July 2004 and incorporated in the state of Nevada. The Company subsequently reincorporated in the state of Delaware in November 2015. The Company has its corporate headquarters in Flagstaff, Arizona. The Company has developed proprietary technology for managing animal pest populations through fertility control. The Company believes that its innovative non-lethal approach, targeting reproduction, is more humane, less harmful to the environment, and more effective in providing a sustainable solution to pest infestations than traditional lethal pest management methods. Its first fertility control product candidate, ContraPest, is marketed for use in controlling the rat population. The innovative compound is consumed by rats and leaves them non-reproductive without other observable side effects. The Company is pursuing regulatory approvals for ContraPest in various jurisdictions, including the United States (“U.S.”), India, Argentina and the European Union (“EU”). On August 23, 2015, the Company submitted ContraPest for registration with the U.S. Environmental Protection Agency (“EPA”), and the EPA granted registration approval for ContraPest effective August 2, 2016. Following regulatory approval for ContraPest, the Company plans to commercialize and distribute ContraPest by leveraging new and existing third party relationships with manufacturing, marketing and distribution partners in the U.S. and internationally. Potential Need for Additional Capital In the course of its research and development activities, the Company has sustained operating losses since its inception and expects such losses to continue for the near future. The Company’s ultimate success depends upon the outcome of a combination of factors, including: (i) the success of its research and development; (ii) regulatory approval and commercialization of ContraPest and its other product candidates; (iii) market acceptance and commercial viability of ContraPest and other products if the Company obtains the necessary regulatory approvals; (iv) the ability to market its products and establish an effective sales force and marketing infrastructure to generate significant revenue; (v) the ability to retain and attract key personnel to develop, operate and grow its business; and (vi) the timely and successful completion of additional financing as needed. The Company has funded its operations to date through the sale of convertible preferred stock and common stock, including an initial public offering of 1,875,000 shares of its common stock on December 8, 2016, debt financing, consisting primarily of convertible notes and, to a lesser extent, payments received in connection with research grants and licensing fees. As of March 31, 2017, the Company had cash and cash equivalents and highly liquid investments of $8,324. Based upon its current operating plan, the Company expects that cash and cash equivalents and highly liquid, short term investments at March 31, 2017, in combination with anticipated revenue, will be sufficient to fund its current operations for the foreseeable future. However, for reasons detailed above, the Company may require additional capital and would have to continue to fund its operating losses and research and development activities in the near term by issuing additional debt and equity instruments. If such equity or debt financing is not available at adequate levels, the Company will need to reevaluate its plans. All amounts shown in these financial statements are in thousands, except percentages and per share and share amounts. Per share and share amounts reflect post-reverse split values. Basis of Presentation The accompanying unaudited condensed financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. In the Company’s opinion, the unaudited condensed financial statements include all material adjustments, all of which are of a normal and recurring nature, necessary to present fairly the Company’s financial position as of March 31, 2017, the Company’s operating results for the three months ended March 31, 2017 and 2016, and the Company’s cash flows for the three months ended March 31, 2017 and 2016. The accompanying financial information as of December 31, 2016 is derived from audited financial statements. Interim results are not necessarily indicative of results for a full year. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, as amended. All amounts shown in these financial statements are in thousands, except percentages and per share and share amounts.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 2 - Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The significant estimates in the Company’s financial statements include the valuation of preferred stock, common stock and related warrants, and other stock-based awards. Actual results could differ from such estimates. Reclassifications Certain prior year amounts have been reclassified to conform to the current period presentation. These reclassifications had no impact on net earnings, financial position or cash flows. Deferred Offering Costs Deferred offering costs consisted primarily of legal, accounting and other direct and incremental fees and costs related to the Company’s initial public offering on December 8, 2016. Deferred offering costs of $2,234 were offset against the proceeds received from the initial public offering in December 2016.There were no deferred offering costs at March 31, 2017. Cash and Cash Equivalents The Company considers money market fund investments to be cash equivalents. The Company had cash equivalents of $43 and $0 at March 31, 2017 and December 31, 2016, respectively included in cash as reported. Investments In Securities Held To Maturity The Company uses cash holdings to purchase highly liquid, short term, investment grade securities diversified among security types, industries and issuers. All of the Company’s investment securities are measured at fair value. The Company’s investment securities primarily consist of municipal debt securities, corporate bonds, U.S. agency securities and commercial paper and highly-liquid money market funds. Accounts Receivable Accounts receivable consist primarily of trade receivables. The Company provides an allowance for doubtful trade receivables equal to the estimated uncollectible amounts. That estimate is based on historical collection experience, current economic and market conditions and a review of the current status of each customer's trade accounts receivable. The allowance for doubtful trade receivables was $0 as of March 31, 2017 and December 31, 2016 as the Company believes all of its receivables are fully collectable. Inventories Inventories are stated at the lower of cost or market value, using the first-in, first-out convention. Inventories consist of raw materials and finished goods. As of March 31, 2017 and December 31, 2016, the Company had inventories of $111 and $57, respectively. Prepaid Expenses Prepaid expenses consist primarily of payments made for director compensation to be fully earned by June 30, 2017 as well as payments made for director and officer insurance, rent and legal deposits to be expensed in the current year. Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Equipment held under capital leases are stated at the present value of minimum lease payments less accumulated amortization. Depreciation on property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. The cost of leasehold improvements is amortized over the life of the improvement or the term of the lease, whichever is shorter. Equipment held under capital leases is amortized over the shorter of the lease term or estimated useful life of the asset. The Company incurs maintenance costs on its major equipment. Repair and maintenance costs are expensed as incurred. Impairment of Long-Lived Assets Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require long-lived assets or asset groups to be tested for possible impairment, the Company compares the undiscounted cash flows expected to be generated from the use of the asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques, such as discounted cash flow models and the use of third- party independent appraisals. The Company has not recorded an impairment of long-lived assets since its inception. Revenue Recognition The Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies when (i) persuasive evidence of an arrangement exists; (ii) the performance of service has been rendered to a customer or delivery has occurred; (iii) the amount of fee to be paid by a customer is fixed and determinable; and (iv) the collectability of the fee is reasonably assured. The Company has generated revenue from a license agreement with a strategic partner, pursuant to which the Company had granted to such partner the exclusive right to manufacture and distribute its product, ContraPest, once the required regulatory approvals were received (See Note 14). This licensing agreement was subsequently terminated on January 23, 2017 (See Note 14). The terms of the licensing agreement contained multiple elements or deliverables, as discussed below. Management evaluates whether the arrangement involving the multiple deliverables contains more than one unit of accounting. To determine the units of accounting under a multiple-element arrangement, management evaluates certain separation criteria, including whether the deliverables have stand-alone value, based on the relevant facts and circumstances of the arrangement. The Company determined that the license granted pursuant to the license agreement did not have stand-alone value and, therefore, the nonrefundable, upfront license fee payments received by the Company are recognized on a straight-line basis over the estimated related performance period (i.e. from the effective date of the agreement through the estimated completion date of the Company’s substantive performance obligations). In accordance with the terms of the license agreement, the Company was also to receive a future fixed amount of contingent milestone payments (i.e. post-regulatory approval license fees) and contingent sales-based royalties to be received upon the achievement of certain milestone events. The milestone events under the agreement include regulatory approval, patent issuance or alternative intellectual property coverage, and sales-based events. The Company did not earn or receive any of the potential contingent milestone payments, as the milestone events to receive such post-approval license fees and sales-based royalties were not achieved. The Company recognizes revenue that is contingent upon the achievement of a substantive milestone event in its entirety in the period in which the milestone is achieved. A milestone is considered substantive when the consideration payable to the Company for such milestone has all of the following characteristics: (i) there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved; (ii) the event can only be achieved based in whole or part on either the Company’s performance or a specific outcome resulting from the Company’s performance; and (iii) if achieved, the event would result in additional payments being due to the Company. As the potential contingent consideration was to be received only upon the achievement of milestone events that are considered substantive, the Company would only recognize such revenue in the period the milestone is achieved and the milestone payments are due and collectible. In addition, the Company accounts for sales-based royalties as revenue upon achievement of certain sales milestones. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue on the balance sheet. Amounts expected to be recognized as revenue in the next twelve months following the balance sheet date are classified as a current liability. The Company recognizes other revenue earned from pilot studies upon the performance of specific services under the respective service contract. To date, the Company has generated minimal revenue from the commercial sales of products. Research and Development Research and development costs are expensed as incurred. Research and development expenses primarily consist of salaries and benefits for research and development employees, stock-based compensation, consulting fees, lab supplies, and costs incurred related to conducting scientific trials and field studies, and regulatory compliance costs. Also, included in research and development expenses is an allocation of facilities related costs, including depreciation of research and development equipment. Stock-based Compensation Employee stock-based awards, consisting of restricted stock units and stock options expected to be settled in shares of the Company’s common stock, are recorded as equity awards. The grant date fair value of these awards is measured using the Black-Scholes option pricing model. The Company expenses the grant date fair value of its stock options on a straight-line basis over their respective vesting periods. Performance-based awards are expensed over the performance period when the related performance goals are probable of being achieved. For equity instruments issued to non-employees, the stock-based consideration is measured using a fair value method. The measurement of the stock-based compensation is subject to re-measurement as the underlying equity instruments vest. The stock-based compensation expense recorded for the three months ended March 31, 2017 and 2016 is as follows: Three Months Ended March 31, 2017 2016 Research and development $ 94 $ 87 General and administrative 967 1,044 Total stock-based compensation expense $ 1,061 $ 1,131 Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax bases of assets and liabilities and net operating loss carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. The Company records net deferred tax assets to the extent it believes these assets will more likely than not be realized. These deferred tax assets are subject to periodic assessments as to recoverability and if it is determined that it is more likely than not that the benefits will not be realized, valuation allowances are recorded which would increase the provision for income taxes. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. In November 2015, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update No. 2015-17, Balance Sheet Classification of Deferred Taxes The Company applies a more-likely-than-not recognition threshold for all tax uncertainties. Only those benefits that have a greater than fifty percent likelihood of being sustained upon examination by the taxing authorities are recognized. Based on its evaluation, the Company has concluded there are no significant uncertain tax positions requiring recognition in its financial statements. The Company recognizes interest and/or penalties related to uncertain tax positions in income tax expense. There are no uncertain tax positions as of March 31, 2017 or December 31, 2016 and as such, no interest or penalties were recorded in income tax expense. Comprehensive Loss Net loss and comprehensive loss were the same for all periods presented; therefore, a separate statement of comprehensive loss is not included in the accompanying financial statements. Loss Per Share Attributable to Common Stockholders Basic loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted loss per share attributable to common stockholders is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock and if-converted methods. For purposes of the computation of diluted loss per share attributable to common stockholders, the Series A convertible preferred stock (prior to its conversion into common stock), Series B convertible preferred stock (prior to its conversion into common stock), convertible promissory notes (prior to their conversion), common stock purchase warrants, and common stock options are considered to be potentially dilutive securities but have been excluded from the calculation of diluted loss per share attributable to common stockholders because their effect would be anti-dilutive given the net loss reported for the three months ended March 31, 2017 and 2016. Therefore, basic and diluted loss per share attributable to common stockholders was the same for all periods presented. The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted loss per share attributable to common stockholders (in common stock equivalent shares): March 31, 2017 2016 Series A convertible preferred stock — 400,000 Series B convertible preferred stock — 454,581 Convertible promissory notes — 533,031 Common stock purchase warrants 829,284 710,487 Restricted stock unit 855,430 — Common stock options 1,502,300 1,556,867 Total 3,187,014 3,654,966 In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern In May 2014 the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers. Since ASU 2014-09 was issued, several additional ASUs have been issued to clarify various elements of the guidance. These standards provide guidance on recognizing revenue, including a five-step model to determine when revenue recognition is appropriate. The standard requires that an entity recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Adoption of the new standard is effective for reporting periods beginning after December 15, 2017. We plan to use the modified retrospective method of adoption and will adopt the standard as of January 1, 2018, the beginning of our next fiscal year. We have completed an initial evaluation of the potential impact from adopting the new standard, including a detailed review of performance obligations for all material revenue streams. Based on this initial evaluation, we do not expect adoption will have a material impact on our financial position, results of operations, or cash flows. Related disclosures will be expanded in line with the requirements of the standard. We will continue our evaluation until our adoption of the new standard. In January 2016, the FASB issued Accounting Standards Update No. 2016-01, Financial Instruments — Overall: Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic230): Classification of Certain Cash Receipts and Cash Payments

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Note 3 - Fair Value Measurements The carrying amounts of certain of the Company’s financial instruments, including cash equivalents, accounts receivable and accounts payable approximate their fair values due to their short maturities. Assets and liabilities recorded at fair value on a recurring basis in the balance sheets, as well as assets and liabilities measured at fair value on a non-recurring basis or disclosed at fair value, are categorized based upon the level of judgment associated with inputs used to measure their fair values. The accounting guidance for fair value provides a framework for measuring fair value, and requires certain disclosures about how fair value is determined. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The accounting guidance also establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows: Level 1 Level 2 Level 3 The Company’s cash equivalents, which include money market funds, are classified as Level 1 because they are valued using quoted market prices. The Company’s marketable securities consist of held to maturity securities and are generally classified as Level 2 because their value is based on valuations using significant inputs derived from or corroborated by observable market data. In certain cases where there is limited activity or less transparency around the inputs to valuation, securities are classified as Level 3. Level 3 liabilities consist of common stock warrant liability. Items Measured at Fair Value on a Recurring Basis The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): March 31, 2017 Level 1 Level 2 Level 3 Total Financial Assets: Money market funds $ 43 $ — $ — $ 43 Corporate fixed income debt securities — 2,961 — 2,961 Total $ 43 $ 2,961 $ — $ 3,004 Financial Liabilities: Common stock warrant liability (1) $ — $ — $ 60 $ 60 Total $ — $ — $ 60 $ 60 December 31, 2016 Level 1 Level 2 Level 3 Total Financial Assets: None $ — $ — $ — $ — Financial Liabilities: Common stock warrant liability (1) $ — $ — $ 69 $ 69 Total $ — $ — $ 69 $ 69 (1) The change in the fair value of the common stock warrant and convertible notes payable for the three months ended March 31, 2017 was recorded as a decrease to other income (expense) and interest expense of $9, in the statements of operations and comprehensive loss. Financial Instruments Not Carried at Fair Value The carrying amounts of the Company’s financial instruments, including accounts payable and accrued liabilities, approximate fair value due to their short maturities. The estimated fair value of the convertible notes and other notes, not recorded at fair value, are recorded at cost or amortized cost which was deemed to estimate fair value.

Investments In Securities Held

Investments In Securities Held To Maturity	3 Months Ended
	Mar. 31, 2017
Investments, Debt and Equity Securities [Abstract]
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	Note 4 - Investments In Securities Held To Maturity As of March 31, 2017, investment in securities held to maturity primarily consisted of corporate fixed income securities and commercial paper. The Company did not have investments prior to the first quarter of 2017. The Company classifies all investments as held to maturity as these investments are short term, highly liquid investments which we intend to hold to maturity. Held to maturity securities are recorded at cost and gains and losses are only recognized as the sale or redemption of the securities is realized. Realized gains and losses are included in non-operating other income (expense) on the condensed statement of operations and are derived using the specific identification method for determining the cost of the securities sold. During the three months ended March 31, 2017, the Company had a minimal amount of net realized gain (loss) on investments recorded. Interest and dividends on investments held to maturity are included in interest and other income, net, in the condensed statements of operations. The following is a summary of held to maturity securities at March 31, 2017: March 31, 2017 Contractual Cost Gross Unrealized Gross Unrealized Fair Market Mutual funds $ - $ - $ - $ - Corporate fixed income securities Less than 12 months 1,315 - (1 ) 1,314 Commercial paper Less than 12 months 1,646 1 - 1,647 Total investments $ 2,961 $ 1 $ (1 ) $ 2,961

Prepaid Expenses

Prepaid Expenses	3 Months Ended
	Mar. 31, 2017
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses Disclosure [Text Block]	Note 5 - Prepaid Expenses Prepaid expenses consist of the following: March 31, December 31, 2017 2016 Director compensation $ 86 $ 215 Director and officer insurance 98 70 Legal retainer 25 25 Rent 25 17 Engineering, software licenses and other 13 10 Total prepaid expenses $ 247 $ 337

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 6 - Property and Equipment Property and equipment, net consist of the following: March 31, December 31, Useful Life 2017 2016 Research and development equipment 5 years $ 1,103 $ 989 Office and computer equipment 3 years 244 235 Furniture and fixtures 7 years 23 17 Leasehold improvements * 189 189 1,559 1,430 Less accumulated depreciation and amortization 857 799 Total $ 702 $ 631 * Shorter of lease term or estimated useful life Depreciation and amortization expense was approximately $59 and $46 for the three months ended March 31, 2017 and 2016, respectively.

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2017
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 7 - Accrued Expenses Accrued expenses consist of the following: March 31, December 31, 2017 2016 Compensation and related benefits $ 386 $ 82 Accrued Litigation 274 286 Other 2 3 Total accrued expenses $ 662 $ 371

Accrued Contract Cancellation S

Accrued Contract Cancellation Settlement	3 Months Ended
	Mar. 31, 2017
Accrued Contract Cancellation Settlement Disclosure [Abstract]
Accrued Contract Cancellation Settlement Disclosure [Text Block]	Note 8 - Accrued Contract Cancellation Settlement The accrued contract cancellation settlement of $1,000 was a result of the Company entering into a settlement agreement with Neogen Corporation in which Neogen and the Company agreed to (a) terminate the existing Exclusive License Agreement between the Company and Neogen dated May 15, 2014 (the “License Agreement”), with neither Neogen or the Company having any further obligations thereunder (other than certain confidentiality obligations); (b) dismiss with prejudice the court action filed by Neogen in the District Court for the District of Arizona on January 19, 2017 (the “Court Action”); and (c) mutually release any and all existing or future claims between the parties and their affiliates related to or arising from the License Agreement or the Court Action. Under the terms of the agreement, the Company agreed to make a one-time payment in the amount of $1,000 in settlement of all claims and termination of all existing contracts between the parties. This payment was made in January, 2017. See note 15 for further details.

Borrowings

Borrowings	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 9 - Borrowings A summary of the Company’s borrowings, including capital lease obligations, is as follows: March 31, December 31, Short-term debt: 2017 2016 Current portion of long-term debt 50 45 Total short-term debt $ 50 $ 45 Long-term debt: Capital lease obligations $ 50 $ 51 Other unsecured promissory notes 141 132 Total 191 183 Less: current portion of long-term debt (50 ) (45 ) Total long-term debt $ 141 $ 138 Capital Lease Obligations Capital lease obligations are for computer and lab equipment leased through Great American and Thermo Fisher. These capital leases expire at various dates through May 2020. Also included in the table above are two notes payable to Direct Capital for the financing of fixed assets.

Notes Payable, Related Parties

Notes Payable, Related Parties	3 Months Ended
	Mar. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 10 - Notes Payable, Related Parties A summary of the Company’s notes payable, related parties is as follows: March 31, December 31, 2017 2016 Unsecured promissory note, interest rate of 4.25% and 8% per annum $ 26 $ 36 Less: current portion of notes payable, related parties 26 30 Total notes payable, long-term $ - $ 6 In April 2013, the Company and a previous employee entered into an agreement to settle all outstanding obligations consisting of a promissory note of $40, dated March 2009, and deferred salaries amounting to $72. The note and salary obligation continue to bear interest at 8% and 4.25%, respectively. The note requires monthly payments of $1 and matures in April 2018. The deferred salary obligation requires monthly payments of $1 and matures in May 2018. Amounts outstanding on these obligations were $26 and $36 at March 31, 2017 and December 31, 2016, respectively. Interest expense on the notes payable, related parties, was $1 and $56 for the three months ended March 31, 2017 and the year ended December 31, 2016 respectively.

Common Stock Warrants and Commo

Common Stock Warrants and Common Stock Warrant Liability	3 Months Ended
	Mar. 31, 2017
Warrants and Rights Note Disclosure [Abstract]
Warrants Note Disclosure [Text Block]	Note 11 - Common Stock Warrants and Common Stock Warrant Liability The table summarizes the common stock warrant activity as of March 31, 2017 as follows: Number of Date Common Stock Warrants Warrants Issued Term Exercise Price Outstanding at December 31, 2015 610,487 Initial Public Offering Underwriter 187,500 December 2016 5 years $ 9.60 Marketing and Development Services 100,000 February 2016 5 years (1) $ 7.50 Other Advisory Services 40,000 August 2016 3 years (1) $ 7.50 Promissory Notes 9,031 March 2016 3 years (1) $ 7.50 Warrants issued 336,531 Warrants exercised 117,733 Outstanding at December 31, 2016 829,285 Warrants issued - Warrants exercised - Outstanding at March 31, 2017 829,285 (1) The warrants also terminate, if not exercised (i) within two years of the closing of an initial public offering of common stock; or (ii) a liquidation, dissolution or winding up of the Company. Secured Promissory Note, 2014/2015 Convertible Notes, Other Promissory Notes; Common Stock Warrants In conjunction with the issuance of the Secured Promissory Note, 2014/2015 Convertible Notes, and certain other promissory notes, the Company issued detachable common stock warrants (“Warrants”) to purchase an aggregate 270,400 shares of common stock, with an exercise price of $7.50 per share. The Warrants were exercisable until the earlier of (i) 5 years from the date of grant; (ii) the closing of an initial public offering of common stock by the Company; and (iii) the closing of liquidation, dissolution or winding up of the Company. The Warrants have a net share settlement (cashless exercise) provision. With this provision the holder may, in lieu of payment of the exercise price in cash, surrender the warrant and receive a net amount of shares based on the fair market value of the common stock at the time of exercise of the warrant after deduction of the aggregate exercise price. However, the Warrants would be exercised automatically in full pursuant to the net exercise provision, without any further action on behalf of the holder, immediately prior to the time the Warrants would otherwise terminate. The Warrants are considered freestanding instruments as (i) they were transferred together with the notes issued but exist independently as a separate security; (ii) they may be exercised separately from the notes; and (iii) they are exercisable for a specific period (term) and do not impact the notes if and when exercised. The Company estimated the fair value of the Warrants at issuance using a Monte Carlo option pricing model based on the following significant inputs: common stock price of $7.50 to $7.575; comparable company volatility of 58.0% to 76.7%; risk- free rates of 1.31% to 1.76%; and the probability of an equity event occurring. The Company reflected the amounts recorded for the Warrants issued within stockholders’ deficit, as additional paid-in-capital. Although the Warrants are a derivative that can be net share settled, the Warrants are considered indexed to the Company’s common stock and the Company has the ability to settle the warrant contract in common shares and met the conditions within the contract to classify the Warrants as an equity instrument. Common Stock Warrant Issued for Marketing and Development Services In February 2016, the Company issued to a stockholder a warrant to purchase 100,000 shares of common stock at an exercise price of $7.50 per share as consideration for providing marketing and development services in Southeast Asia. The warrant was fully vested and exercisable on the date of grant. The common stock warrant has the similar features as the Warrants discussed above, except it is exercisable until the earlier of (i) five years from the date of grant; (ii) two years after the closing of an initial public offering of common stock by the Company; and (iii) the closing of a liquidation, dissolution or winding up of the Company. The Company estimated the fair value of the common stock warrant to be $431 on the date of grant using a Black- Scholes option pricing model based on the following significant inputs : March 2016 Promissory Notes Common Stock Warrants In March 2016, the Company issued certain unsecured notes with common stock warrants to purchase an aggregate of 9,032 shares of common stock at an exercise price of $7.50 per share. The common stock warrants are exercisable until the earlier of (i) three years from the date of grant; (ii) two years after the closing of an initial public offering of common stock; and (iii) the closing of a liquidation, dissolution or winding up of the Company. The Company estimated the fair value of the common stock warrants on the date of grant using a Monte Carlo pricing model based on the following significant inputs: common stock price of $7.575; comparable company volatility 79.6%; and risk-free rate of 1.49%. August 2016 Other Advisory Services On August 16, 2016, the Company issued to each of two advisors warrants to purchase 20,000 shares of common stock at an exercise price of $7.50 per share as consideration for providing advisory services to the Company. The warrants were fully vested and exercisable on the date of grant until the earlier of (i) three years from the date of grant; (ii) two years after the closing of an initial public offering of common stock; and (iii) the closing of a liquidation, dissolution or winding up of the Company. The Company recorded the fair value of the warrants as stock-based compensation expense within general and administrative expense on the date of grant. Common Stock Warrant Issued To Initial Public Offering Underwriter In December 2016, the Company issued to the underwriter of its IPO a warrant to purchase 100,000 shares of common stock at an exercise price of $9.60 per share as consideration for providing services in connection with the Company’s initial public offering. The warrant was fully vested and exercisable on the date of grant. The common stock warrant is exercisable until five years from the date of grant. The Company estimated the fair value of the common stock warrant to be $939 on the date of grant using a Black- Scholes option pricing model based on the following significant inputs : University of Arizona Common Stock Warrant In connection with the June 2015 amended and restated exclusive license agreement with the University of Arizona (“University”), the Company issued to the University a common stock warrant to purchase 15,000 shares of common stock at an exercise price of $7.50 per share. The warrant was fully vested and exercisable on the date of grant, and expires, if not exercised, five years from the date of grant. In the event of a “terminating change” of the Company, as defined in the warrant agreement, the warrant holder would be paid in cash the aggregate fair market value of the underlying shares immediately prior to the consummation of the terminating change event. Due to the cash settlement provision, the derivative warrant liability was recorded at fair value and is revalued at the end of each reporting period. The changes in fair value are reported in other income (expense) in the statements of operations and comprehensive loss. The estimated fair value of the derivative warrant liability was $53 at the date of grant. The estimated fair value of the derivative warrant liability was $61 at March 31, 2017. As this derivative warrant liability is revalued at the end of each reporting period, the fair values as determined at the date of grant and subsequent periods was based on the following significant inputs using a Monte Carlo option pricing model: common stock price of $7.91; comparable company volatility of 77.7% of the underlying common stock; risk-free rates of 1.93%; and dividend yield of 0%; including the probability assessment of a terminating change event occurring. The change in fair value of the derivative warrant liability was $9 for the three months ended March 31, 2017 and was recorded in other income (expense) in the accompanying statements of operations and comprehensive loss. July 2015 Consulting Agreement Common Stock Warrant In July 2015, the Company issued a common stock warrant to purchase 121,227 shares of common stock, with an exercise price of $7.50 per share, as consideration for services under a consulting arrangement. The warrant was fully vested and exercisable on the date of grant. This common stock warrant has the similar features as the Warrants described above, except it is exercisable until the earlier of (i) ten years from the date of grant; (ii) two years after the closing of an initial public offering of common stock by the Company; and (iii) the closing of a liquidation, dissolution or winding up of the Company. The estimated the fair value of the common stock warrant on the date of grant was $537 as determined by using a Black-Scholes option pricing model based on the following significant inputs: common stock price of $7.575; comparable company volatility of 60.9%; expected term of 6.25 years; risk-free rate of 2.09%; and dividend yield of 0%. The Company recorded the fair value of the, warrant as stock-based compensation expense within general and administrative expense in the accompanying statements of operations and comprehensive loss in 2015. Northern Arizona University Common Stock Warrant In November 2015, the Company issued a common stock warrant to purchase 210,526 shares of common stock at an exercise price of $15.00 per share to Northern Arizona University (“NAU”) as part of the consideration given with the Series A convertible preferred stock in exchange for the full cancellation of the NAU Promissory Note.

Stockholders' Deficit

Stockholders' Deficit	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 12 - Stockholders’ Deficit Common Stock The Company had 10,161,042 and 10,157,292 shares of common stock issued and outstanding as of March 31, 2017 and December 31, 2016, respectively. During the three months ended March 31, 2017, the Company issued an aggregate of 3,750 shares of common stock to a consultant for services, valued at $31.

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 13 - Stock-based Compensation Effective December 2008, the Company established the 2008 – 2009 Non-Qualified Stock Option Plan (the “2008 – 2009 Plan”) under which 20,000 stock options remain outstanding at March 31, 2017. The stock-based awards were issued with a price not less than $15.00 per share or 100% of the fair value of a share of common stock on the date of grant. After July 2015, no further awards were granted under the 2008 – 2009 Plan. Such outstanding awards will continue to be governed by their existing terms under the 2008 – 2009 Plan. Effective July 2015, the Company’s stockholders approved the 2015 Equity Incentive Plan (the “2015 Plan”), which permits the issuance of up to 2,000,000 shares reserved for the grant of stock options, stock appreciation rights, restricted stock units and other stock-based awards for employees, directors or consultants of the Company. The Board of Directors and the Company’s stockholders approved an additional 1,000,000 shares of common stock for issuance under the 2015 Plan, effective September 26, 2016. The stock-based awards are generally issued with a price equal to no less than fair value at the date of grant. Options granted under the 2015 Plan generally vest immediately, or ratably over a two- to 36-month period coinciding with their respective service periods; however, participants may exercise their options prior to vesting as provided by the 2015 Plan. Unvested shares issued for option exercised early may be subject to a repurchase by the Company if the participant terminates at the original exercise price. Options under the 2015 Plan generally have a contractual term of five or ten years. Certain stock option awards provide for accelerated vesting upon a change in control or an initial public offering. As of March 31, 2017, the Company had 994,480 shares of common stock available for issuance under the 2015 Plan. The Company measures the fair value of stock options with service-based and performance-based vesting criteria to employees, directors and consultants on the date of grant using the Black-Scholes option pricing model. The fair value of equity instruments issued to non-employees is re-measured as the award vests. The Black-Scholes valuation model requires the Company to make certain estimates and assumptions, including assumptions related to the expected price volatility of the Company’s stock, the period under which the options with be outstanding, the rate of return on risk-free investments, and the expected dividend yield for the Company’s stock. The weighted-average assumptions used in the Black-Scholes option-pricing model used to calculate the fair value of options granted during the three months ended March 31, 2017, were as follows: Employee Non-Employee Expected volatility 79.8% -83.7 % N/A Expected dividend yield — N/A Expected term (in years) 3.25 N/A Risk-free interest rate 1.87%-1.94 % N/A Due to the Company’s limited operating history and lack of company-specific historical or implied volatility, the expected volatility assumption was determined based on historical volatilities from traded options of biotech companies of comparable in size and stability, whose share prices are publicly available. The expected term of options granted to employees is calculated based on the mid-point between the vesting date and the end of the contractual term according to the simplified method as described in SEC Staff Accounting Bulletin 110 because the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its awards have been outstanding. For non-employee options, the expected term of options granted is the contractual term of the options. The risk-free rate by reference to the implied yields of U.S. Treasury securities with a remaining term equal to the expected term assumed at the time of grant. The expected dividend assumption is based on the Company’s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends. The table summarizes the stock option activity, for both plans, for the periods indicated as follows: Number of Weighted Weighted Aggregate Outstanding at December 31, 2016 1,477,300 1.61 5.8 $ 9,662 Granted 25,000 $ 8.04 5.0 $ - Exercised - $ - - $ - Forfeited - $ - - $ - Expired - $ - - $ - Outstanding at March 31, 2017 1,502,300 1.72 5.5 $ 9,299 Exercisable at March 31, 2017 1,044,286 $ 1.28 5.3 $ 6,924 (1) The aggregate intrinsic value on the table was calculated based on the difference between the estimated fair value of the Company’s stock and the exercise price of the underlying option. The estimated stock values used in the calculation was $7.91 and $8.15 per share for the three months ended March 31, 2017 and the year ended December 31, 2016, respectively. The stock-based compensation expense was recorded as follows: Three Months Ended March 31, 2017 2016 Research and development $ 94 $ 87 General and administrative 967 1,044 Total stock-based compensation expense $ 1,061 $ 1,131 The allocation between research and development and general and administrative expense was based on the department and services performed by the employee or non-employee. At March 31, 2017, the total compensation cost related to non-vested options not yet recognized was $3,892, which will be recognized over a weighted average period of four years, assuming the employees complete their service period required for vesting. Restricted Stock Units The following table summarizes restricted stock unit activity for the three months ended March 31, 2017: Number of Weighted Average Outstanding as of December 31, 2016 455,430 $ 0.76 Granted 40,000 (1) $ 8.35 Vested (40,000 ) $ 8.35 Forfeited — $ — Outstanding as of March 31, 2017 455,430 $ 0.76 (1) 40,000 restricted stock units were granted on March 27, 2017 with a weighted average grant date fair value of $8.35 and vested immediately. The RSUs were settled for shares in April 2017.

License and Other Agreements

License and Other Agreements	3 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative Arrangement Disclosure [Text Block]	Note 14 - License and Other Agreements Neogen Corporation In May 2014, the Company entered into an exclusive license agreement with Neogen Corporation (“Neogen”). The Company granted an exclusive license to Neogen to (i) use the Company’s intellectual property (“IP”), consisting primarily of the ContraPest technology and (ii) manufacture, distribute and sell commercial rodent control products in the United States and certain U.S. territories, Canada and Mexico. As previously disclosed in our Current Report on Form 8-K, on January 23, 2017 we entered into a termination agreement (the “Settlement Agreement”) with Neogen. Pursuant to the Settlement Agreement, the parties agreed to (a) terminate the existing Exclusive License Agreement between us and Neogen dated May 15, 2014 (the “License Agreement”), with neither Neogen or us having any further obligations thereunder (other than certain confidentiality obligations); (b) dismiss with prejudice the court action filed by Neogen in the District Court for the District of Arizona on January 19, 2017 (the “Court Action”), as further described below; and (c) mutually release any and all existing or future claims between the parties and their affiliates related to or arising from the License Agreement or the Court Action. As part of the Settlement Agreement, we agreed to pay to Neogen upon the execution of the Settlement Agreement an aggregate of $1,000 in settlement of all claims. For the three months ended March 31, 2017 and the year ended December 31, 2016, the Company recognized revenue of $0 and $186 under the License Agreement. Bioceres/INMET S.A. Agreement In January 2016, the Company entered into a services agreement with Bioceres, Inc. (“Bioceres”), a wholly-owned subsidiary of Bioceres S.A., a leading agricultural biotechnology company in Argentina, and its Argentinean subsidiary, Ingenieria Metabolica S.A. (“INMET”) to develop a production method for synthetic triptolide, the main ingredient in ContraPest. The Company also entered into an agency agreement with INMET whereby the Company appointed INMET as its exclusive agent to seek regulatory approval for and conduct pre-sales and marketing of its product, ContraPest, in Argentina. The Company and INMET have also agreed to manufacture and distribute its product in Argentina and other countries, as mutually agreed, through a newly formed entity. The term of the service agreement is for two years. The service agreement can be terminated at any time upon written notice by either party for any reason. The term of the agency agreement with INMET is the earlier of: (i) when the Company and INMET incorporate the joint venture entity in Argentina or (ii) January 2018.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 15 - Commitments and Contingencies Legal Proceedings The Company may be subject to legal proceedings and claims arising from contracts or other matters from time to time in the ordinary course of business. Management is not aware of any pending or threatened litigation where the ultimate disposition or resolution could have a material adverse effect on its financial position, results of operations or liquidity. Neogen Settlement Agreement See Note 13 for a description of the Settlement Agreement with Neogen related to the License Agreement. Although notice of the legal action by Neogen and the subsequent agreement to terminate existing agreements with Neogen, occurred after December 31, 2016, per the provisions of Accounting Standards Codification Topic 450 Loss Contingencies, included in the financial statements of the Company at December 31, 2016 is a $1,000 charge to general and administrative expenses and a corresponding accrual of contract cancellation settlement agreement related to the License Agreement. Resolution of Dispute In recognition of his continued support and cooperation, and to resolve a dispute regarding whether his options appropriately expired in the first quarter of 2016, in July 2016, the Company’s Board of Directors agreed to issue to its former chief executive officer 120,000 shares of the Company’s common stock. The expense of $300 associated with this full and final settlement was recorded at December 31, 2016. Lease Commitments Rent expense was $78 and $234 for the three months ended and year ended March 31, 2017 and December 31, 2016, respectively. The future minimum lease payments under non-cancellable operating lease and future minimum capital lease payments as of March 31, 2017 are as follows: Capital Operating Years Ending December 31, 2017 19 274 2018 18 258 2019 10 221 2020 3 - Total minimum lease payments $ 50 $ 753 Capital Less: amounts representing interest (6.39%, ranging from 10.48% to 11.56%) $ 6 Present value of minimum lease payments 44 Less: current installments under capital lease obligations 20 Total long-term portion $ 24

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 16 - Subsequent Events In April 2017, the Company issued 40,000 shares of its common stock to a vice president of the Company in settlement of a restricted stock grant made in March 2017. In April 2017, the Company also issued 667 shares of its common stock to a consultant in settlement of fees due him at December 31, 2016. Also in April 2017, the Company issued 14,014 shares of its common stock to an executive of the Company in connection with a cashless exercise of a fully vested option grant with an option exercise price of $0.50 per share.

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The significant estimates in the Company’s financial statements include the valuation of preferred stock, common stock and related warrants, and other stock-based awards. Actual results could differ from such estimates.
Reclassification, Policy [Policy Text Block]	Reclassifications Certain prior year amounts have been reclassified to conform to the current period presentation. These reclassifications had no impact on net earnings, financial position or cash flows.
Deferred Charges, Policy [Policy Text Block]	Deferred Offering Costs Deferred offering costs consisted primarily of legal, accounting and other direct and incremental fees and costs related to the Company’s initial public offering on December 8, 2016. Deferred offering costs of $2,234 were offset against the proceeds received from the initial public offering in December 2016.There were no deferred offering costs at March 31, 2017.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers money market fund investments to be cash equivalents. The Company had cash equivalents of $43 and $0 at March 31, 2017 and December 31, 2016, respectively included in cash as reported.
Marketable Securities, Held-to-maturity Securities, Policy [Policy Text Block]	Investments In Securities Held To Maturity The Company uses cash holdings to purchase highly liquid, short term, investment grade securities diversified among security types, industries and issuers. All of the Company’s investment securities are measured at fair value. The Company’s investment securities primarily consist of municipal debt securities, corporate bonds, U.S. agency securities and commercial paper and highly-liquid money market funds.
Receivables, Policy [Policy Text Block]	Accounts Receivable Accounts receivable consist primarily of trade receivables. The Company provides an allowance for doubtful trade receivables equal to the estimated uncollectible amounts. That estimate is based on historical collection experience, current economic and market conditions and a review of the current status of each customer's trade accounts receivable. The allowance for doubtful trade receivables was $0 as of March 31, 2017 and December 31, 2016 as the Company believes all of its receivables are fully collectable.
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or market value, using the first-in, first-out convention. Inventories consist of raw materials and finished goods. As of March 31, 2017 and December 31, 2016, the Company had inventories of $111 and $57, respectively.
Prepaid Expenses [Policy Text Block]	Prepaid Expenses Prepaid expenses consist primarily of payments made for director compensation to be fully earned by June 30, 2017 as well as payments made for director and officer insurance, rent and legal deposits to be expensed in the current year.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Equipment held under capital leases are stated at the present value of minimum lease payments less accumulated amortization. Depreciation on property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. The cost of leasehold improvements is amortized over the life of the improvement or the term of the lease, whichever is shorter. Equipment held under capital leases is amortized over the shorter of the lease term or estimated useful life of the asset. The Company incurs maintenance costs on its major equipment. Repair and maintenance costs are expensed as incurred.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require long-lived assets or asset groups to be tested for possible impairment, the Company compares the undiscounted cash flows expected to be generated from the use of the asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques, such as discounted cash flow models and the use of third- party independent appraisals. The Company has not recorded an impairment of long-lived assets since its inception.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies when (i) persuasive evidence of an arrangement exists; (ii) the performance of service has been rendered to a customer or delivery has occurred; (iii) the amount of fee to be paid by a customer is fixed and determinable; and (iv) the collectability of the fee is reasonably assured. The Company has generated revenue from a license agreement with a strategic partner, pursuant to which the Company had granted to such partner the exclusive right to manufacture and distribute its product, ContraPest, once the required regulatory approvals were received (See Note 14). This licensing agreement was subsequently terminated on January 23, 2017 (See Note 14). The terms of the licensing agreement contained multiple elements or deliverables, as discussed below. Management evaluates whether the arrangement involving the multiple deliverables contains more than one unit of accounting. To determine the units of accounting under a multiple-element arrangement, management evaluates certain separation criteria, including whether the deliverables have stand-alone value, based on the relevant facts and circumstances of the arrangement. The Company determined that the license granted pursuant to the license agreement did not have stand-alone value and, therefore, the nonrefundable, upfront license fee payments received by the Company are recognized on a straight-line basis over the estimated related performance period (i.e. from the effective date of the agreement through the estimated completion date of the Company’s substantive performance obligations). In accordance with the terms of the license agreement, the Company was also to receive a future fixed amount of contingent milestone payments (i.e. post-regulatory approval license fees) and contingent sales-based royalties to be received upon the achievement of certain milestone events. The milestone events under the agreement include regulatory approval, patent issuance or alternative intellectual property coverage, and sales-based events. The Company did not earn or receive any of the potential contingent milestone payments, as the milestone events to receive such post-approval license fees and sales-based royalties were not achieved. The Company recognizes revenue that is contingent upon the achievement of a substantive milestone event in its entirety in the period in which the milestone is achieved. A milestone is considered substantive when the consideration payable to the Company for such milestone has all of the following characteristics: (i) there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved; (ii) the event can only be achieved based in whole or part on either the Company’s performance or a specific outcome resulting from the Company’s performance; and (iii) if achieved, the event would result in additional payments being due to the Company. As the potential contingent consideration was to be received only upon the achievement of milestone events that are considered substantive, the Company would only recognize such revenue in the period the milestone is achieved and the milestone payments are due and collectible. In addition, the Company accounts for sales-based royalties as revenue upon achievement of certain sales milestones. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue on the balance sheet. Amounts expected to be recognized as revenue in the next twelve months following the balance sheet date are classified as a current liability. The Company recognizes other revenue earned from pilot studies upon the performance of specific services under the respective service contract. To date, the Company has generated minimal revenue from the commercial sales of products.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are expensed as incurred. Research and development expenses primarily consist of salaries and benefits for research and development employees, stock-based compensation, consulting fees, lab supplies, and costs incurred related to conducting scientific trials and field studies, and regulatory compliance costs. Also, included in research and development expenses is an allocation of facilities related costs, including depreciation of research and development equipment.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-based Compensation Employee stock-based awards, consisting of restricted stock units and stock options expected to be settled in shares of the Company’s common stock, are recorded as equity awards. The grant date fair value of these awards is measured using the Black-Scholes option pricing model. The Company expenses the grant date fair value of its stock options on a straight-line basis over their respective vesting periods. Performance-based awards are expensed over the performance period when the related performance goals are probable of being achieved. For equity instruments issued to non-employees, the stock-based consideration is measured using a fair value method. The measurement of the stock-based compensation is subject to re-measurement as the underlying equity instruments vest. The stock-based compensation expense recorded for the three months ended March 31, 2017 and 2016 is as follows: T hree Months Ended March 31, 2017 2016 Research and development $ 94 $ 87 General and administrative 967 1,044 Total stock-based compensation expense $ 1,061 $ 1,131
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax bases of assets and liabilities and net operating loss carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. The Company records net deferred tax assets to the extent it believes these assets will more likely than not be realized. These deferred tax assets are subject to periodic assessments as to recoverability and if it is determined that it is more likely than not that the benefits will not be realized, valuation allowances are recorded which would increase the provision for income taxes. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. In November 2015, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update No. 2015-17, Balance Sheet Classification of Deferred Taxes The Company applies a more-likely-than-not recognition threshold for all tax uncertainties. Only those benefits that have a greater than fifty percent likelihood of being sustained upon examination by the taxing authorities are recognized. Based on its evaluation, the Company has concluded there are no significant uncertain tax positions requiring recognition in its financial statements. The Company recognizes interest and/or penalties related to uncertain tax positions in income tax expense. There are no uncertain tax positions as of March 31, 2017 or December 31, 2016 and as such, no interest or penalties were recorded in income tax expense.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss Net loss and comprehensive loss were the same for all periods presented; therefore, a separate statement of comprehensive loss is not included in the accompanying financial statements.
Earnings Per Share, Policy [Policy Text Block]	Loss Per Share Attributable to Common Stockholders Basic loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted loss per share attributable to common stockholders is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock and if-converted methods. For purposes of the computation of diluted loss per share attributable to common stockholders, the Series A convertible preferred stock (prior to its conversion into common stock), Series B convertible preferred stock (prior to its conversion into common stock), convertible promissory notes (prior to their conversion), common stock purchase warrants, and common stock options are considered to be potentially dilutive securities but have been excluded from the calculation of diluted loss per share attributable to common stockholders because their effect would be anti-dilutive given the net loss reported for the three months ended March 31, 2017 and 2016. Therefore, basic and diluted loss per share attributable to common stockholders was the same for all periods presented. The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted loss per share attributable to common stockholders (in common stock equivalent shares): March 31, 2017 2016 Series A convertible preferred stock — 400,000 Series B convertible preferred stock — 454,581 Convertible promissory notes — 533,031 Common stock purchase warrants 829,284 710,487 Restricted stock unit 855,430 — Common stock options 1,502,300 1,556,867 Total 3,187,014 3,654,966 In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern In May 2014 the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers. Since ASU 2014-09 was issued, several additional ASUs have been issued to clarify various elements of the guidance. These standards provide guidance on recognizing revenue, including a five-step model to determine when revenue recognition is appropriate. The standard requires that an entity recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Adoption of the new standard is effective for reporting periods beginning after December 15, 2017. We plan to use the modified retrospective method of adoption and will adopt the standard as of January 1, 2018, the beginning of our next fiscal year. We have completed an initial evaluation of the potential impact from adopting the new standard, including a detailed review of performance obligations for all material revenue streams. Based on this initial evaluation, we do not expect adoption will have a material impact on our financial position, results of operations, or cash flows. Related disclosures will be expanded in line with the requirements of the standard. We will continue our evaluation until our adoption of the new standard. In January 2016, the FASB issued Accounting Standards Update No. 2016-01, Financial Instruments — Overall: Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic230): Classification of Certain Cash Receipts and Cash Payments

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	The stock-based compensation expense recorded for the three months ended March 31, 2017 and 2016 is as follows: Three Months Ended March 31, 2017 2016 Research and development $ 94 $ 87 General and administrative 967 1,044 Total stock-based compensation expense $ 1,061 $ 1,131
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted loss per share attributable to common stockholders (in common stock equivalent shares): March 31, 2017 2016 Series A convertible preferred stock — 400,000 Series B convertible preferred stock — 454,581 Convertible promissory notes — 533,031 Common stock purchase warrants 829,284 710,487 Restricted stock unit 855,430 — Common stock options 1,502,300 1,556,867 Total 3,187,014 3,654,966

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): March 31, 2017 Level 1 Level 2 Level 3 Total Financial Assets: Money market funds $ 43 $ — $ — $ 43 Corporate fixed income debt securities — 2,961 — 2,961 Total $ 43 $ 2,961 $ — $ 3,004 Financial Liabilities: Common stock warrant liability (1) $ — $ — $ 60 $ 60 Total $ — $ — $ 60 $ 60 December 31, 2016 Level 1 Level 2 Level 3 Total Financial Assets: None $ — $ — $ — $ — Financial Liabilities: Common stock warrant liability (1) $ — $ — $ 69 $ 69 Total $ — $ — $ 69 $ 69 (1) The change in the fair value of the common stock warrant and convertible notes payable for the three months ended March 31, 2017 was recorded as a decrease to other income (expense) and interest expense of $9, in the statements of operations and comprehensive loss.

Investments In Securities Hel25

Investments In Securities Held To Maturity (Tables)	3 Months Ended
	Mar. 31, 2017
Investments, Debt and Equity Securities [Abstract]
Held-to-maturity Securities [Table Text Block]	The following is a summary of held to maturity securities at March 31, 2017: March 31, 2017 Contractual Cost Gross Unrealized Gross Unrealized Fair Market Mutual funds $ - $ - $ - $ - Corporate fixed income securities Less than 12 months 1,315 - (1 ) 1,314 Commercial paper Less than 12 months 1,646 1 - 1,647 Total investments $ 2,961 $ 1 $ (1 ) $ 2,961

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	3 Months Ended
	Mar. 31, 2017
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	Prepaid expenses consist of the following: March 31, December 31, 2017 2016 Director compensation $ 86 $ 215 Director and officer insurance 98 70 Legal retainer 25 25 Rent 25 17 Engineering, software licenses and other 13 10 Total prepaid expenses $ 247 $ 337

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment, net consist of the following: March 31, December 31, Useful Life 2017 2016 Research and development equipment 5 years $ 1,103 $ 989 Office and computer equipment 3 years 244 235 Furniture and fixtures 7 years 23 17 Leasehold improvements * 189 189 1,559 1,430 Less accumulated depreciation and amortization 857 799 Total $ 702 $ 631 * Shorter of lease term or estimated useful life

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2017
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consist of the following: March 31, December 31, 2017 2016 Compensation and related benefits $ 386 $ 82 Accrued Litigation 274 286 Other 2 3 Total accrued expenses $ 662 $ 371

Borrowings (Tables)

Borrowings (Tables)	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	A summary of the Company’s borrowings, including capital lease obligations, is as follows: March 31, December 31, Short-term debt: 2017 2016 Current portion of long-term debt 50 45 Total short-term debt $ 50 $ 45 Long-term debt: Capital lease obligations $ 50 $ 51 Other unsecured promissory notes 141 132 Total 191 183 Less: current portion of long-term debt (50 ) (45 ) Total long-term debt $ 141 $ 138

Notes Payable, Related Parties

Notes Payable, Related Parties (Tables)	3 Months Ended
	Mar. 31, 2017
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]	A summary of the Company’s notes payable, related parties is as follows: March 31, December 31, 2017 2016 Unsecured promissory note, interest rate of 4.25% and 8% per annum $ 26 $ 36 Less: current portion of notes payable, related parties 26 30 Total notes payable, long-term $ - $ 6

Common Stock Warrants and Com31

Common Stock Warrants and Common Stock Warrant Liability (Tables)	3 Months Ended
	Mar. 31, 2017
Warrants and Rights Note Disclosure [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	The table summarizes the common stock warrant activity as of March 31, 2017 as follows: Number of Date Common Stock Warrants Warrants Issued Term Exercise Price Outstanding at December 31, 2015 610,487 Initial Public Offering Underwriter 187,500 December 2016 5 years $ 9.60 Marketing and Development Services 100,000 February 2016 5 years (1) $ 7.50 Other Advisory Services 40,000 August 2016 3 years (1) $ 7.50 Promissory Notes 9,031 March 2016 3 years (1) $ 7.50 Warrants issued 336,531 Warrants exercised 117,733 Outstanding at December 31, 2016 829,285 Warrants issued - Warrants exercised - Outstanding at March 31, 2017 829,285 (1) The warrants also terminate, if not exercised (i) within two years of the closing of an initial public offering of common stock; or (ii) a liquidation, dissolution or winding up of the Company.

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The weighted-average assumptions used in the Black-Scholes option-pricing model used to calculate the fair value of options granted during the three months ended March 31, 2017, were as follows: Employee Non-Employee Expected volatility 79.8% -83.7 % N/A Expected dividend yield — N/A Expected term (in years) 3.25 N/A Risk-free interest rate 1.87%-1.94 % N/A
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The table summarizes the stock option activity, for both plans, for the periods indicated as follows: Number of Weighted Weighted Aggregate Outstanding at December 31, 2016 1,477,300 1.61 5.8 $ 9,662 Granted 25,000 $ 8.04 5.0 $ - Exercised - $ - - $ - Forfeited - $ - - $ - Expired - $ - - $ - Outstanding at March 31, 2017 1,502,300 1.72 5.5 $ 9,299 Exercisable at March 31, 2017 1,044,286 $ 1.28 5.3 $ 6,924 (1) The aggregate intrinsic value on the table was calculated based on the difference between the estimated fair value of the Company’s stock and the exercise price of the underlying option. The estimated stock values used in the calculation was $7.91 and $8.15 per share for the three months ended March 31, 2017 and the year ended December 31, 2016, respectively.
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]	The stock-based compensation expense was recorded as follows: Three Months Ended March 31, 2017 2016 Research and development $ 94 $ 87 General and administrative 967 1,044 Total stock-based compensation expense $ 1,061 $ 1,131
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	The following table summarizes restricted stock unit activity for the three months ended March 31, 2017: Number of Weighted Average Outstanding as of December 31, 2016 455,430 $ 0.76 Granted 40,000 (1) $ 8.35 Vested (40,000 ) $ 8.35 Forfeited — $ — Outstanding as of March 31, 2017 455,430 $ 0.76 (1) 40,000 restricted stock units were granted on March 27, 2017 with a weighted average grant date fair value of $8.35 and vested immediately. The RSUs were settled for shares in April 2017.

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block]	Rent expense was $78 and $234 for the three months ended and year ended March 31, 2017 and December 31, 2016, respectively. The future minimum lease payments under non-cancellable operating lease and future minimum capital lease payments as of March 31, 2017 are as follows: Capital Operating Years Ending December 31, 2017 19 274 2018 18 258 2019 10 221 2020 3 - Total minimum lease payments $ 50 $ 753 Capital Less: amounts representing interest (6.39%, ranging from 10.48% to 11.56%) $ 6 Present value of minimum lease payments 44 Less: current installments under capital lease obligations 20 Total long-term portion $ 24

Organization and Description 34

Organization and Description of Business (Details Textual) - USD ($) $ in Thousands	Dec. 08, 2016	Mar. 31, 2017
Cash, Cash Equivalents, and Short-term Investments		$ 8,324
Common Stock [Member]
Stock Issued During Period, Shares, New Issues	1,875,000

Summary of Significant Accoun35

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Total stock-based compensation expense	$ 1,061	$ 1,131
Research and Development Expense [Member]
Total stock-based compensation expense	94	87
General and Administrative Expense [Member]
Total stock-based compensation expense	$ 967	$ 1,044

Summary of Significant Accoun36

Summary of Significant Accounting Policies (Details 1) - shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Total	3,187,014	3,654,966
Restricted Stock Units (RSUs) [Member]
Total	855,430	0
Series A Convertible Preferred Stock [Member]
Total	0	400,000
Series B Convertible Preferred Stock [Member]
Total	0	454,581
Convertible Debt Securities [Member]
Total	0	533,031
Warrant [Member]
Total	829,284	710,487
Employee Stock Option [Member]
Total	1,502,300	1,556,867

Summary of Significant Accoun37

Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Deferred Offering Costs	$ 0	$ 2,234
Cash Equivalents, at Carrying Value	43	0
Allowance for Doubtful Accounts Receivable, Current	0	0
Inventory, Net	$ 111	$ 57

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands		Mar. 31, 2017	Dec. 31, 2016
Financial Assets:
Held-to-maturity Securities, Fair Value		$ 2,961
Fixed Income Securities [Member]
Financial Assets:
Held-to-maturity Securities, Fair Value		1,314
Fair Value, Measurements, Recurring [Member]
Financial Assets:
Assets, Fair Value Disclosure		3,004
Financial Liabilities:
Common stock warrant liability	[1]	60	$ 69
Financial Liabilities Fair Value Disclosure		60	69
Fair Value, Measurements, Recurring [Member] | Corporate Debt Securities [Member]
Financial Assets:
Held-to-maturity Securities, Fair Value		2,961
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Financial Assets:
Assets, Fair Value Disclosure		43
Financial Liabilities:
Common stock warrant liability	[1]	0	0
Financial Liabilities Fair Value Disclosure		0	0
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member] | Corporate Debt Securities [Member]
Financial Assets:
Held-to-maturity Securities, Fair Value		0
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Financial Assets:
Assets, Fair Value Disclosure		2,961
Financial Liabilities:
Common stock warrant liability	[1]	0	0
Financial Liabilities Fair Value Disclosure		0	0
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member] | Corporate Debt Securities [Member]
Financial Assets:
Held-to-maturity Securities, Fair Value		2,961
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Financial Assets:
Assets, Fair Value Disclosure		0
Financial Liabilities:
Common stock warrant liability	[1]	60	69
Financial Liabilities Fair Value Disclosure		60	$ 69
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member] | Corporate Debt Securities [Member]
Financial Assets:
Held-to-maturity Securities, Fair Value		0
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member]
Financial Assets:
Held-to-maturity Securities, Fair Value		43
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Financial Assets:
Held-to-maturity Securities, Fair Value		43
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Financial Assets:
Held-to-maturity Securities, Fair Value		0
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Financial Assets:
Held-to-maturity Securities, Fair Value		$ 0
[1]	The change in the fair value of the common stock warrant and convertible notes payable for the three months ended March 31, 2017 was recorded as a decrease to other income (expense) and interest expense of $9, in the statements of operations and comprehensive loss.

Fair Value Measurements (Deta39

Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Adjustment of Warrants	$ (9)	$ 2

Investments In Securities Hel40

Investments In Securities Held To Maturity (Details) $ in Thousands	Mar. 31, 2017USD ($)
Schedule of Held-to-maturity Securities [Line Items]
Cost	$ 2,961
Gross Unrealized Gains	1
Gross Unrealized Losses	(1)
Fair Market Value	2,961
Fixed Income Securities [Member]
Schedule of Held-to-maturity Securities [Line Items]
Cost	1,315
Gross Unrealized Gains	0
Gross Unrealized Losses	(1)
Fair Market Value	1,314
Mutual Fund [Member]
Schedule of Held-to-maturity Securities [Line Items]
Cost	0
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Fair Market Value	0
Commercial Paper [Member]
Schedule of Held-to-maturity Securities [Line Items]
Cost	1,646
Gross Unrealized Gains	1
Gross Unrealized Losses	0
Fair Market Value	$ 1,647

Prepaid Expenses (Details)

Prepaid Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Director compensation	$ 86	$ 215
Director and officer insurance	98	70
Legal retainer	25	25
Rent	25	17
Engineering, software licenses and other	13	10
Total prepaid expenses	$ 247	$ 337

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment, Gross		$ 1,559	$ 1,430
Less accumulated depreciation and amortization		857	799
Total		702	631
Office and Computer Equipment [Member]
Property, Plant and Equipment, Gross		$ 244	235
Property, Plant and Equipment, Useful Life		3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment, Gross		$ 23	17
Property, Plant and Equipment, Useful Life		7 years
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross		$ 189	189
Property, Plant and Equipment, Useful Life	[1]	0 years
Research and Development Equipment [Member]
Property, Plant and Equipment, Gross		$ 1,103	$ 989
Property, Plant and Equipment, Useful Life		5 years
[1]	Shorter of lease term or estimated useful life

Property and Equipment (Detai43

Property and Equipment (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation, Depletion and Amortization, Nonproduction	$ 59	$ 46

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Compensation and related benefits	$ 386	$ 82
Accrued Litigation	274	286
Other	2	3
Total accrued expenses	$ 662	$ 371

Accrued Contract Cancellation45

Accrued Contract Cancellation Settlement (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Accrued Contract Cancellation Settlement Disclosure [Abstract]
Accrued Contract Cancellation Settlement Liabilities	$ 0	$ 1,000

Borrowings (Details)

Borrowings (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Short-term debt:
Current portion of long-term debt	$ 50	$ 45
Total short-term debt	50	45
Long-term debt:
Capital lease obligations	50	51
Other unsecured promissory notes	141	132
Total	191	183
Less: current portion of long-term debt	(50)	(45)
Total long-term debt	$ 141	$ 138

Notes Payable, Related Partie47

Notes Payable, Related Parties (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Related Party Transactions [Abstract]
Unsecured promissory note, interest rate of 4.25% and 8% per annum	$ 26	$ 36
Less: current portion of notes payable, related parties	26	30
Total notes payable, long-term	$ 0	$ 6

Notes Payable, Related Partie48

Notes Payable, Related Parties (Details Textual) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended
	Apr. 30, 2013	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Long-term Debt, Gross	$ 40
Due to Employees	$ 72
Interest Expense, Related Party		$ 1	$ 17	$ 56
Notes Payable, Related Parties, Noncurrent		$ 0		$ 6
Salary Obligation [Member]
Related Party Transaction, Rate	4.25%
Debt Instrument, Periodic Payment	$ 1
Debt Instrument, Maturity Date	May 31, 2018
Unsecured Promissory Note [Member]
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%		4.25%
Debt Instrument, Periodic Payment	$ 1
Debt Instrument, Maturity Date	Apr. 30, 2018

Common Stock Warrants and Com49

Common Stock Warrants and Common Stock Warrant Liability (Details) - $ / shares		3 Months Ended	12 Months Ended
		Mar. 31, 2017	Dec. 31, 2016	Aug. 16, 2016	Mar. 31, 2016	Feb. 29, 2016	Nov. 30, 2015	Jul. 31, 2015	Jun. 30, 2015
Number of Warrants, Outstanding		829,285	610,487
Class of Warrant or Right Issued		0	336,531
Class of Warrant or Right Exercised		0	117,733
Number of Warrants, Outstanding		829,285	829,285
Initial Public Offering Underwriter Warrants [Member]
Class of Warrant or Right Issued			187,500
Class of Warrant or Right, Date Issued			Dec. 31, 2016
Class of Warrant or Right, Expiration Term			5 years
Class of Warrant or Right, Exercise Price			$ 9.60
Marketing and Development Services Warrants [Member]
Class of Warrant or Right Issued			100,000
Class of Warrant or Right, Date Issued			Feb. 28, 2016
Class of Warrant or Right, Expiration Term	[1]		5 years
Class of Warrant or Right, Exercise Price			$ 7.50
Promissory Notes Warrants [Member]
Class of Warrant or Right Issued			9,031
Class of Warrant or Right, Date Issued			Mar. 31, 2016
Class of Warrant or Right, Expiration Term	[1]		3 years
Class of Warrant or Right, Exercise Price			$ 7.50
Other Advisory Services Warrants [Member]
Class of Warrant or Right Issued			40,000
Class of Warrant or Right, Date Issued			Aug. 31, 2016
Class of Warrant or Right, Expiration Term	[1]		3 years
Class of Warrant or Right, Exercise Price			$ 7.50
Common Stock Warrants [Member]
Class of Warrant or Right, Exercise Price		$ 7.50
Common Stock Warrant Issued To Initial Public Offering Underwriter [Member]
Class of Warrant or Right, Exercise Price			$ 9.60
August 2016 Other Advisory Services [Member]
Class of Warrant or Right, Exercise Price				$ 7.50
March 2016 Promissory Notes Common Stock Warrants [Member]
Class of Warrant or Right, Exercise Price					$ 7.50
Common Stock Warrant Issued for Marketing and Development Services [Member]
Class of Warrant or Right, Exercise Price						$ 7.50
Northern Arizona University Common Stock Warrant [Member]
Class of Warrant or Right, Exercise Price							$ 15
July 2015 Consulting Agreement Common Stock Warrant [Member]
Class of Warrant or Right, Exercise Price								$ 7.50
University of Arizona Common Stock Warrant [Member]
Class of Warrant or Right, Exercise Price									$ 7.50
[1]	The warrants also terminate, if not exercised (i) within two years of the closing of an initial public offering of common stock; or (ii) a liquidation, dissolution or winding up of the Company.

Common Stock Warrants and Com50

Common Stock Warrants and Common Stock Warrant Liability (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended				3 Months Ended
	Dec. 31, 2016	Mar. 31, 2016	Feb. 29, 2016	Jul. 31, 2015	Mar. 31, 2017	Mar. 31, 2016	Aug. 16, 2016	Nov. 30, 2015	Jun. 30, 2015
Share Price	$ 8.15				$ 7.91
Fair Value Adjustment of Warrants					$ (9)	$ 2
Common Stock Warrant Issued for Marketing and Development Services [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 7.50
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used			Black- Scholes option pricing model
Share Price			$ 7.57
Warrants Not Settleable in Cash, Fair Value Disclosure			$ 431
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate			77.80%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term			3 years 9 months
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate			0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate			2.09%
Common Stock Warrant Issued To Initial Public Offering Underwriter [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 9.60
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used	Black- Scholes option pricing model
Share Price	$ 8
Warrants Not Settleable in Cash, Fair Value Disclosure	$ 939
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	82.10%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.92%
March 2016 Promissory Notes Common Stock Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		9,032				9,032
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 7.50				$ 7.50
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used		Monte Carlo pricing model
Share Price		$ 7.575				$ 7.575
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		79.60%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		1.49%
July 2015 Consulting Agreement Common Stock Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				121,227
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 7.50
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used				Black-Scholes option pricing model
Share Price				$ 7.575
Warrants Not Settleable in Cash, Fair Value Disclosure				$ 537
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate				60.90%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term				6 years 3 months
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate				0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				2.09%
University of Arizona Common Stock Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									15,000
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 7.50
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used					Monte Carlo option pricing model
Share Price					$ 7.91
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate					77.70%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate					0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate					1.93%
Derivative Liability					$ 61				$ 53
Fair Value Adjustment of Warrants					$ 9
Common Stock Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					270,400
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 7.50
Class Of Warrant Or Right, Terms					5 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used					Monte Carlo option pricing model
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum					58.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum					76.70%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum					1.31%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum					1.76%
Common Stock Warrants [Member] | Maximum [Member]
Share Price					$ 7.575
Common Stock Warrants [Member] | Minimum [Member]
Share Price					$ 7.50
Other Advisory Services Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 7.50
Promissory Notes Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	7.50
Initial Public Offering Underwriter Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	9.60
Marketing and Development Services Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 7.50
August 2016 Other Advisory Services [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							20,000
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 7.50
Northern Arizona University Common Stock Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								210,526
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 15

Stockholders' Deficit (Details

Stockholders' Deficit (Details Textual) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Jul. 31, 2016	Mar. 31, 2017	Dec. 31, 2016
Common Stock, Shares, Issued		10,161,042	10,157,292
Common Stock, Shares, Outstanding		10,161,042	10,157,292
Chief Executive Officer [Member]
Stock Issued During Period, Shares, Issued for Services	120,000
Consultant [Member]
Stock Issued During Period, Shares, Issued for Services		3,750
Stock Issued During Period, Value, Issued for Services		$ 31

Stock-based Compensation (Detai

Stock-based Compensation (Details) - Employee [Member]	3 Months Ended
	Mar. 31, 2017
Expected volatility, Minimum	79.80%
Expected volatility, Maximum	83.70%
Expected dividend yield	0.00%
Expected term (in years)	3 years 3 months
Risk-free interest rate, Minimum	1.87%
Risk-free interest rate, Maximum	1.94%

Stock-based Compensation (Det53

Stock-based Compensation (Details 1) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended	12 Months Ended
		Mar. 31, 2017	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Options Outstanding, Beginning		1,477,300
Number of Options, Granted		25,000
Number of Options, Exercised		0
Number of Options, Forfeited		0
Number of Options, Expired		0
Number of Options Outstanding, Ending		1,502,300	1,477,300
Number of Options, Exercisable		1,044,286
Weighted Average Exercise Price Per Share Outstanding, Beginning		$ 1.61
Weighted Average Exercise Price Per Share, Granted		8.04
Weighted Average Exercise Price Per Share, Exercised		0
Weighted Average Exercise Price Per Share, Forfeited		0
Weighted Average Exercise Price Per Share, Expired		0
Weighted Average Exercise Price Per Share Outstanding, Ending		1.72	$ 1.61
Weighted Average Exercise Price Per Share Outstanding, Exercisable		$ 1.28
Weighted Average Remaining Contractual Term (years)		5 years 6 months	5 years 9 months 18 days
Weighted Average Remaining Contractual Term (years), Granted		5 years
Weighted Average Remaining Contractual Term (years), Exercisable		5 years 3 months 18 days
Aggregate Intrinsic Value, Beginning	[1]	$ 9,662
Aggregate Intrinsic Value, Ending	[1]	9,299	$ 9,662
Aggregate Intrinsic Value, Exercisable	[1]	$ 6,924
[1]	The aggregate intrinsic value on the table was calculated based on the difference between the estimated fair value of the Company's stock and the exercise price of the underlying option. The estimated stock values used in the calculation was $7.91 and $8.15 per share for the three months ended March 31, 2017 and the year ended December 31, 2016, respectively.

Stock-based Compensation (Det54

Stock-based Compensation (Details 2) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Allocated Share-based Compensation Expense	$ 1,061	$ 1,131
Research and Development Expense [Member]
Allocated Share-based Compensation Expense	94	87
General and Administrative Expense [Member]
Allocated Share-based Compensation Expense	$ 967	$ 1,044

Stock-based Compensation (Det55

Stock-based Compensation (Details 3) - $ / shares	1 Months Ended	3 Months Ended
	Mar. 27, 2017	Mar. 31, 2017
Number of Units Outstanding, Beginning		455,430
Number of Units, Granted		40,000
Number of Units, Vested		(40,000)
Number of Units, Forfeited		0
Number of Units Outstanding, Ending		455,430
Weighted Average Grant-Date Fair Value Per Units Outstanding, Beginning		$ 0.76
Weighted Average Grant-Date Fair Value Per Units Outstanding, Granted		8.35
Weighted Average Grant-Date Fair Value Per Units Outstanding, Vested		8.35
Weighted Average Grant-Date Fair Value Per Units Outstanding, Forfeited		0
Weighted Average Grant-Date Fair Value Per Units Outstanding, Ending		$ 0.76
Restricted Stock Units (RSUs) [Member]
Number of Units, Granted	40,000
Weighted Average Grant-Date Fair Value Per Units Outstanding, Granted	$ 8.35

Stock-based Compensation (Det56

Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended
	Mar. 27, 2017	Sep. 26, 2016	Mar. 31, 2017	Dec. 31, 2016	Jul. 31, 2015
Share Price			$ 7.91	$ 8.15
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized			$ 3,892
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			4 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			40,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 8.35
Equity Incentive Plan 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		1,000,000
Common Stock, Capital Shares Reserved for Future Issuance			994,480
Non-Qualified Stock Option Plan 2008-2009 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number			20,000
Share Based Compensation Arrangements By Share Based Payment Award, Basis Price Per Share			$ 15
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent			100.00%
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	40,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 8.35

License and Other Agreements (D

License and Other Agreements (Details Textual) - Neogen Corporation [Member] - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Jan. 23, 2017	Mar. 31, 2017	Dec. 31, 2016
License and Services Revenue		$ 0	$ 186
Litigation Settlement, Amount	$ 1,000

Commitments and Contingencies58

Commitments and Contingencies (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Capital Leases, 2017	$ 19
Capital Leases, 2018	18
Capital Leases, 2019	10
Capital Leases, 2020	3
Capital Leases, Total minimum lease payments	50
Operating Lease, 2017	274
Operating Lease, 2018	258
Operating Lease, 2019	221
Operating Lease, 2020	0
Operating Lease, Total minimum lease payments	753
Less: amounts representing interest (6.39%, ranging from 10.48% to 11.56%)	6
Present value of minimum lease payments	44
Less: current installments under capital lease obligations	20
Total long-term portion	$ 50	$ 51

Commitments and Contingencies59

Commitments and Contingencies (Details) (Parenthetical) - Capital Lease Obligations [Member]	Mar. 31, 2017
Debt Instrument, Interest Rate, Effective Percentage [Abstract]
Capital Leases of Lessee, Contingent Rentals, Basis Spread on Variable Rate	6.39%
Minimum [Member]
Debt Instrument, Interest Rate, Effective Percentage [Abstract]
Capital Leases of Lessee, Contingent Rentals, Basis Spread on Variable Rate	10.48%
Maximum [Member]
Debt Instrument, Interest Rate, Effective Percentage [Abstract]
Capital Leases of Lessee, Contingent Rentals, Basis Spread on Variable Rate	11.56%

Commitments and Contingencies60

Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended
	Jul. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Share-based Compensation		$ 1,061	$ 1,131
Operating Leases, Rent Expense		$ 78		$ 234
Chief Executive Officer [Member]
Stock Issued During Period, Shares, Issued for Services	120,000
Share-based Compensation				300
Consultant [Member]
Stock Issued During Period, Shares, Issued for Services		3,750
General and Administrative Expense [Member]
Loss Contingency, Loss in Period				$ 1,000

Subsequent Events (Details Text

Subsequent Events (Details Textual) - $ / shares	1 Months Ended		3 Months Ended
	Apr. 30, 2017	Jul. 31, 2016	Mar. 31, 2017
Subsequent Event [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 8.04
Consultant [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Issued for Services			3,750
Chief Executive Officer [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Issued for Services		120,000
Subsequent Event [Member] | Executive Officer [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures	14,014
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.50
Subsequent Event [Member] | Consultant [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Issued for Services	667
Subsequent Event [Member] | Vice President [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues	40,000